Arcutis (ARQT) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
196.5M
Gross Profit
177.4M
90.27%
Operating Income
-128.4M
-65.33%
Net Income
-140.0M
-71.25%
EPS (Diluted)
-$1.16
Balance Sheet Metrics
Total Assets
348.9M
Total Liabilities
191.3M
Shareholders Equity
157.5M
Debt to Equity
1.21
Cash Flow Metrics
Operating Cash Flow
-136.1M
Free Cash Flow
-117.3M
Revenue & Profitability Trend
Arcutis Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 196.5M | 59.6M | 3.7M | 0 | 0 |
| Cost of Goods Sold | 19.1M | 5.0M | 754.0K | 0 | 0 |
| Gross Profit | 177.4M | 54.6M | 2.9M | 0 | 0 |
| Operating Expenses | 305.8M | 295.7M | 304.6M | 206.5M | 136.6M |
| Operating Income | -128.4M | -241.1M | -301.6M | -206.5M | -136.6M |
| Pre-tax Income | -139.4M | -259.0M | -311.5M | -206.4M | -135.7M |
| Income Tax | 647.0K | 3.1M | 0 | 0 | - |
| Net Income | -140.0M | -262.1M | -311.5M | -206.4M | -135.7M |
| EPS (Diluted) | -$1.16 | -$3.78 | -$5.66 | -$4.18 | -$3.80 |
Income Statement Trend
Arcutis Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 335.8M | 330.4M | 437.4M | 402.8M | 292.8M |
| Non-Current Assets | 13.1M | 10.9M | 11.9M | 5.4M | 5.4M |
| Total Assets | 348.9M | 341.4M | 449.3M | 408.2M | 298.3M |
| Liabilities | |||||
| Current Liabilities | 81.0M | 46.7M | 37.8M | 33.3M | 22.6M |
| Non-Current Liabilities | 110.3M | 206.0M | 201.9M | 77.1M | 5.0M |
| Total Liabilities | 191.3M | 252.7M | 239.7M | 110.5M | 27.6M |
| Equity | |||||
| Total Shareholders Equity | 157.5M | 88.7M | 209.6M | 297.7M | 270.6M |
Balance Sheet Composition
Arcutis Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -140.0M | -262.1M | -311.5M | -206.4M | -135.7M |
| Operating Cash Flow | -136.1M | -237.9M | -260.1M | -181.2M | -121.6M |
| Investing Activities | |||||
| Capital Expenditures | -143.0K | -428.0K | -333.0K | -995.0K | -321.0K |
| Investing Cash Flow | 33.8M | 180.2M | -64.2M | -76.0M | -181.8M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 61.7M | 98.9M | 298.9M | 279.8M | 297.0M |
| Free Cash Flow | -117.3M | -247.5M | -281.0M | -175.6M | -113.4M |
Cash Flow Trend
Arcutis Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-12.48
Forward P/E
-14.10
Price to Book
11.55
Price to Sales
7.74
PEG Ratio
-14.10
Profitability Ratios
Profit Margin
-60.95%
Operating Margin
-37.25%
Return on Equity
-70.58%
Return on Assets
-18.43%
Financial Health
Current Ratio
3.55
Debt to Equity
77.67
Beta
1.78
Per Share Data
EPS (TTM)
-$1.04
Book Value per Share
$1.20
Revenue per Share
$1.71
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| arqt | 1.6B | -12.48 | 11.55 | -70.58% | -60.95% | 77.67 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Vera Therapeutics | 1.4B | -8.41 | 2.58 | -39.49% | 0.00% | 10.18 |
| Immunocore Holdings | 1.6B | -31.41 | 4.13 | -5.86% | -6.48% | 114.67 |
| Agios | 1.9B | 2.89 | 1.32 | 60.26% | 1,798.26% | 3.61 |
Financial data is updated regularly. All figures are in the company's reporting currency.